Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Komatsu in connection with the acquisition of Bracke Forest AB
Mandate

Vinge advises Komatsu in connection with the acquisition of Bracke Forest AB

July 01, 2022 Employment and Benefits Corporate Crime & Compliance Intellectual Property M&A Real Estate and Construction Banking and Finance

Vinge advises Komatsu Ltd. and its subsidiary Komatsu Forest AB in connection with the acquisition of Bracke Forest AB, a company that develops and manufactures soil preparation equipment and products for mechanized forest planting.

Vinge’s team consisted primarily of Jonas Johansson, Carl Fredrik Wachtmeister and Philip Moré (M&A), Johan Cederblad (Environment), Ulf Pyk (Real Estate and Banking & Finance), Isabell Nielsen, Lisa Hörnqvist and Karolina Fuhrman (Commercial Agreements, IT and GDPR), Michael Montner and Ian Jonson (IP), Ebba Svenburg (Employment), Tove Tullberg (Compliance) and Emy Rydén (Project Assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024